🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. CF101 1 mg

    Can-Fite BioPharma

    Rheumatoid Arthritis

    phase 3 small molecule terminated

    1 trial

  2. CHAMPIX 0.5 mg film-coated tablets, Placebo CHAMPIX ® 0.5mg Comprimé pelliculé

    Pari Pharma GmbH

    Smokers smoking at least 10 cigarettes/day in the past year

    phase 3 small molecule active

    1 trial

  3. CHLORURE DE SODIUM FRESENIUS 0,9 %, solution injectable, Tislelizumab

    The George Institute

    patients with a positive status for molecular residual disease (MRD) [MRD (+)] 2 to 5 months after the end of standard end of standard curative treatment

    phase 3 small molecule active

    1 trial

  4. CHS-0214

    Coherus Oncology

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  5. CHS-1420

    Coherus Oncology

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  6. CINRYZE 500

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 mab completed

    1 trial

  7. CINRYZE 500 U

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    1 trial

  8. CISPLATIN

    Ningbo Cancer Hospital

    Ovarian epithelial cancer : intraperitoneal resectable relapse

    phase 3 small molecule active

    1 trial

  9. CISPLATIN, BL-B01D1, GEMCITABINE, PEGFILGRASTIM, CARBOPLATIN

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  10. CISPLATIN, CARBOPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, GEMCITABINE, IMJUDO 20 mg/ml concentrate for solution for infusion., INFLIXIMAB, GEMCITABINE

    AstraZeneca AB

    Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer

    phase 3 small molecule active

    1 trial

  11. CISPLATIN, FLUOROURACIL, MITOMYCIN, CAPECITABINE, CAPECITABINE, DOCETAXEL

    CERO THERAPEUTICS HOLDINGS, INC.

    locally advanced anal squamous cell carcinoma

    phase 3 small molecule active

    1 trial

  12. CISPLATIN, GEMCITABINE, INFLIXIMAB, Rilvegostomig, IMFINZI 50 mg/mL concentrate for solution for infusion., DS-8201a, MYCOPHENOLATE MOFETIL

    AstraZeneca AB

    Advanced HER2-expressing Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  13. CISPLATIN, INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., GEMCITABINE, MYCOPHENOLATE MOFETIL

    AstraZeneca AB

    First-line patients with advanced biliary tract cancers (BTC)

    phase 3 small molecule active

    1 trial

  14. CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, OPDIVO 10 mg/mL concentrate for solution for infusion., Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, GEMSOL, 40 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI

    Bristol-Myers Squibb Australia Pty Ltd

    Bladder Cancer Muscle-Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  15. CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS, Placebo to Clostridium Botulinum neurotoxin type A (150 kD)

    Merz Therapeutics GmbH

    Episodic migraine

    phase 3 small molecule active

    1 trial

  16. CLS2901C (human [allogeneic] chondrocyte sheets)

    CellSeed Europe Ltd

    Osteoarthritis of the Knee

    phase 3 mab active

    1 trial

  17. CMF regimen

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 small molecule active

    2 trials

  18. COAGULATION FACTOR VIII , COAGULATION FACTOR VIIA , COAGULATION FACTOR IX , SAR439774, FACTOR VIII INHIBITOR BYPASSING ACTIVITY , ANTITHROMBIN III

    Genzyme Europe B.V.

    Hemophilia A or Hemophilia B

    phase 3 small molecule active

    1 trial

  19. COBALAMIN

    The George Institute

    Hydroxycobalamin deficiency

    phase 3 small molecule active

    1 trial

  20. COLCHICINE OPOCALCIUM 1 mg, comprimé sécable

    Pari Pharma GmbH

    Stroke, Ischemic, TIA, Cardiac Disease, Atherosclerosis, Myocardial Infarction, Coronary Syndrome, Cerebral Infarction

    phase 3 small molecule active

    1 trial

  21. COMP360 psilocybin

    Compass Therapeutics

    PTSD - Post Traumatic Stress Disorder

    phase 3 small molecule active

    1 trial

  22. CONDROSULF 800 mg tabletta

    The George Institute

    Knee osteoarthritis with moderate to severe pain

    phase 3 small molecule active

    1 trial

  23. CONOXIA, gas medicinal comprimido, Conoxia 100% medicinal gas, cryogenic

    The George Institute

    ILD

    phase 3 small molecule active

    1 trial

  24. COPINAL 300 mg cápsulas, Placebo has the same composition than imp except the active substance

    The George Institute

    Chronic liver disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources